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study was to estimate the proportion of cleft palate surgeries identified as secondary 
(or revision) in patients with a diagnosis of cleft palate only or cleft lip and palate. 
Additional objectives included identification and analysis of patient and hospital 
level characteristics. Methods: The Kids’ Inpatient Database (KID), a nationally 
representative sample of pediatric inpatient visits, was used for this study. Years 
analyzed included 2003, 2006, and 2009. Subjects were identified by International 
Classification of Diseases Ninth Revision (ICD-9) diagnosis of cleft palate only or 
cleft lip and palate. Primary surgery was defined as a surgery before three years of 
age with the ICD-9 procedural code ‘Correction Cleft Palate.’ Secondary surgery was 
defined as a surgery at age three or older with any of the following ICD-9 procedural 
codes: ‘Correction Cleft Palate,’ ‘Revision Cleft Palate Repair,’ ‘Closure Fistula Mouth,’ 
or ‘Plastic Repair Palate.’ Hospital, patient, and clinical characteristics were also 
examined across cohorts. All costs were adjusted to 2009 dollars using the Consumer 
Price Index (CPI). Results: For the three years combined, 15,861 discharges for cleft 
palate repair were reported: 7,856 for CP only patients and 8,055 for CLP patients. 
Secondary surgery accounted for 28.1% (N= 2,193) of palate repairs performed in 
children with CP only, compared to 43.5% (N= 3,505) of palate repairs in children 
with CLP. Secondary surgery rates did not differ significantly across years. From 
2003-2009, CPI-adjusted costs decreased in all cohorts except secondary surgery in 
CP only patients. ConClusions: Secondary surgeries represent a significant por-
tion of cleft palate repairs performed in the United States. Children with cleft palate 
only have fewer secondary surgeries compared to those with cleft lip and palate.
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objeCtives: To evaluate prior disease-modifying drug (DMD) use among currently 
treated and currently untreated multiple sclerosis (MS) patients. Methods: A ran-
dom sample of MS patients (age > 18 years) from the National Health and Wellness 
Survey or Lightspeed Research panel completed an internet survey in November/
December 2012. The survey contained questions related to demographics, disease 
characteristics, and current and prior DMD use. The number and percentage of 
patients reporting prior DMD use by current therapy groups (self-injectable DMDs, 
infusion DMDs, oral DMDs, and not currently on DMD) is described. Results: 
There were 969 patients who completed the survey. Average age was 48.8 years (SD 
11.3), 82.9% were female and 737 (76.1%) were currently receiving DMD treatment 
[self-injectable: 576 (78.2%); infusion: 84 (11.4%); oral: 77 (10.4%)]; while 232 (23.9%) 
were currently untreated. Among patients currently treated with a self-injectable 
DMD, most patients were either on their first treatment (57.7%) or had prior use 
of 1 DMD (27.4%). For those currently treated with an infusion DMD, 42.9% had 
prior use of 1 DMD, 36.9% had prior use of 2 DMDs, and 17.9% had prior use of ≥ 3 
DMDs. For patients currently treated with an oral DMD, 27.3% had prior use of 1 
DMD, 32.5% had prior use of 2 DMDs, 32.5% had prior use of ≥ 3 DMDs, and 7.8% 
were initially treated with an oral DMD. For those not currently on a DMD, 34.9% 
were untreated, while 33.2%, 18.5%, and 13.4% had prior use of 1, 2, or ≥ 3 DMDs, 
respectively. ConClusions: In this sample of MS patients, 8.4% had never been 
treated with a DMD. Most patients initiated therapy with a self-injectable DMD, 
while patients currently treated with infusion and oral DMDs had prior use of 1 
or more DMDs.
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objeCtives: Ileocolic anastomoses are commonly performed for right-sided colon 
cancer and Crohn’s disease. Anastomotic leak complications are a significant source 
of patient morbidity and mortality and have a major impact on health care costs. 
The objective of this analysis was to compare anastomotic leak rates following 
ileocolic anastomoses performed using mechanical stapling and hand-sewn suture 
techniques. Methods: Pubmed, Embase, Cochrane Library and trial registries were 
searched for randomized controlled trials comparing hand-sewn and stapled ile-
ocolic anastomoses published between 1990 and December 2013. The odds ratio (OR) 
for overall anastomotic leak rate was calculated and then weighted and pooled in a 
meta-analysis with Mantel-Haenszel fixed-effect modeling with Chi square test for 
heterogeneity. Results: Eight studies with a total of 1,172 patients were included. 
Two studies were from Germany, 2 from Scotland, 1 from France, 1 from Japan, 1 from 
US and 1 was a global study with patients from US, UK and Canada. The median and 
average sample sizes across studies were 112 and 149 patients, respectively. Three 
studies were for Crohn’s disease, 3 were for colorectal cancer and 2 were for other 
diagnoses. There were 11 (2.31%) anastomotic leaks reported in 457 patients in the 
mechanically stapled group, and 44 (6.15%) leaks in 715 patients in the hand-sewn 
(sutures) group. At study level, the median leak rates in stapled and hand-sewn 
groups were 0.40% and 3.95%, respectively. Overall, the odds of anastomotic leaks 
were reduced to less than half with mechanical stapling compared to hand sewn 
techniques (pooled OR = 0.46; 95% CI = 0.24 to 0.89; p = 0.02). ConClusions: This 
meta-analysis of randomized controlled trials comparing hand-sewn with stapled 
ileocolic anastomoses demonstrates a significantly lower rate of anastomotic leak-
gery at age two or older with the ICD-9 procedural code for cleft lip repair. Additional 
characteristics examined across cohorts include length of stay and Consumer Price 
Index (CPI) adjusted charges. Results: A total of 8,385 discharges for cleft lip repair 
were reported. In CL patients secondary surgery represented 16.3% (N= 134), 14.2% 
(N= 105), and 15.1% (N= 129) of surgeries for 2003, 2006, and 2009, respectively. In CLP 
patients secondary surgery represented 25.7% (N= 511), 25.2% (N= 506), and 28.2% 
(N= 555) for 2003, 2006, and 2009, respectively. From 2003-2009, mean length of stay 
and CPI-adjusted costs decreased in all cohorts except secondary surgery in CL 
patients. ConClusions: One fourth of all children required secondary surgery. 
The proportion of secondary cleft lip surgery did not differ significantly across 
years. Once adjusted, costs have decreased for the majority of patients, a finding 
in contrast to previously published studies.
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objeCtives: This study investigated the effect of Medicare Part D on prescribing 
patterns and drug utilization of non-benzodiazepine sedative hypnotics. Methods: 
Time-series analyses were conducted using data from National Ambulatory Medical 
Care Survey (NAMCS). Subjects were derived from US. outpatient visits between 2002 
and 2009 where the primary payment source was Medicare and at least one non-
benzodiazepine sedative hypnotic drug was prescribed. Data trends were graphically 
plotted and further analyzed using segmented regression to estimate the effects of 
the Medicare Part D on drug utilization. A weighted multivariate logistic regression 
was conducted to predict the maximum likelihood of prescribing pattern associated 
with patient and physician socioeconomic characteristics. All analyses utilized SAS 
PROC SURVEY applications to adjust for the complex sampling design employed 
by NAMCS database. Results: An estimated 31.52 million of Medicare beneficiar-
ies received at least one non-benzodiazepine prescription between 2002 and 2009 
during their outpatient visits. After Medicare part D in 2006, there was a notable 
increase (24%) in Medicare outpatient visits between 2006 and 2009. In the same 
time period, prescribing of non-benzodiazepine sedatives increased significantly 
by 46.3%. The results from segmented regression indicate that the implementation 
of Medicare Part D drug benefits has significantly increased the sedative utiliza-
tion in Medicare population (P= 0.0001). Multivariate logistic regression revealed 
that patient gender, geography, chronic condition, and physician specialty all play 
an important role in determining the utilization pattern of non-benzodiazepine 
sedatives. ConClusions: Our study indicated that the use of non-benzodiazepine 
hypnotics increased dramatically after Medicare Part D. Increased utilization may 
also be related to the switching effect from benzodiazepine formulary exclusion 
and/or antidepressant off-label use for insomnia pharmacotherapy. These findings 
show the importance of using data analysis to identify substantial consequences 
from policy implementation and the need to provide additional guidance to insurers 
on how to effectively monitor prescribing patterns.
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objeCtives: To evaluate the burden of 30-day readmissions in adjunctively-treated 
patients with epilepsy. Methods: The MarketScan®retrospective database (Jan-
2006 to Dec-2011) was used. Selected patients had: ≥ 1 diagnosis code for epilepsy 
(ICD-9 345.xx), age ≥ 18, ≥ 1 hospitalization (index), and received adjunctive AEDs 
during study period. Eligible patients had 60 days pre- and ≥ 365 days post-index 
continuous enrolment. Patients were stratified by type of hospitalization (all-cause 
or epilepsy-related) and by partial vs. generalized epilepsy diagnosis. Readmissions 
were defined as any hospitalization occurring < 30 days from the preceding hospi-
talization’s discharge date. Results: Of a total of 504,507 patients, 141,017 (19%; age 
51±17.6; 59% female, average follow-up 1,188 days) had ≥ 1 all-cause hospitalizations, 
and of these, 91,587 (65%) had an epilepsy-related admission, and 41,453 (29%) had 
≥ 1 all-cause 30-day readmissions. Forty-six percent of patients (8,955) had epilepsy-
related readmissions. Among patients with epilepsy-related hospitalizations, 19,115 
(21%) had ≥ 1 all-cause 30-day readmissions, 61% of whom (11,670) had epilepsy-
related readmissions. Partial epilepsy accounted for 9,882 (7%) of the total number 
of patients hospitalized (all-cause) during the study period; 100% of these patients 
had one or more epilepsy-related admissions. Among the hospitalized (all-cause) 
with POS, 1,729 (18%) had ≥ 1 all-cause readmissions, and of these 1,140 (66%) had ≥ 1 
epilepsy-related readmissions. Among POS patients with epilepsy-related hospitali-
zations, 1,502 (15%) had ≥ 1 all-cause readmissions, and of these 1,055 (70%) had ≥ 1 
epilepsy-related readmissions. ConClusions: In this study, approximately one in 
three patients with epilepsy hospitalized for any reason had a 30-day readmission, 
with approximately half of these patients presenting 30-day readmissions due to 
epilepsy. Approximately 60% of patients with an epilepsy-related admission had 
a 30-day readmission due to epilepsy. Patients with partial epilepsy had a greater 
burden of epilepsy-related hospitalizations and readmissions.
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objeCtives: Children with cleft palate (CP) or cleft lip and palate (CLP) may require 
multiple surgeries to improve their appearance and function. The objective of this 
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period 2001-2007. Methods: A logistic regression was performed aspatially and at 
the nodes of a 5 km spacing grid overlaid over Florida and using all the cancer cases 
within a radius of 125 km of each node. Each observation was weighted as a function 
of its proximity to the center of the window (bisquare adaptive weight function). 
Covariates included age, race, marital status, smoking, type of health insurance 
and diagnosis facilities, presence of comorbidities (healthy (no comorbidity), aver-
age (1-2 comorbidities), above-average), census-tract median income and presence 
of farmhouse, year of diagnosis, county-level provider-to-case ratios. Results: 
Variables increasing the likelihood of late-stage diagnosis included having 1 to 2 
comorbidities (odds= 1.697) and more than 2 comorbidities (odds= 3.963), smoking 
(odds= 1.283), being African American (odds= 1.199) and living in census tracts with 
farmhouses (odds= 1.124). Having private insurance (odds= 0.533), having public 
insurance (odds= 0.470), being married (odds= 0.787) or diagnosed in a for-profit 
facility (odds= 0.886), as well as living in census tracts with high income (odds= 0.994) 
reduces the likelihood. ConClusions: There are significant spatial associations 
between late-stage prostate cancer incidence and observed individual, socioeco-
nomic, behavioral, environmental and demographic factors in Florida. This empha-
sizes the need for local strategies and cancer control interventions to reduce the 
percentage of late-stage diagnosis and ultimately eliminate health disparities.
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objeCtives: Differences in cancer incidence and mortality are apparent among vari-
ous demographic groups. Understanding the underlying determinants that place cer-
tain population subgroups at higher incidence and/or mortality of prostate cancer is 
imperative. Analyzing temporal trends can provide a comprehensive picture of the 
burden of the disease and generate new insights about the impact of various interven-
tions. This study aims to use advanced geospatial and temporal statistical techniques 
to model temporal trends in prostate cancer incidence and mortality and their geo-
graphical variations across Florida. Methods: Annual census-tract level rates were 
computed over the period 1981-2007 for two races (white and black), two categories of 
age (40-65, > 65) and five classes of incomes. They were then smoothed using binomial 
kriging to filter the noise caused by small population sizes. Joinpoint regression and new 
disparity statistics were applied to analyze temporal trends and detect potential racial 
and socio-economic differences. Results: Bivariate analysis of time-series indicated 
that late-stage diagnosis was generally more prevalent among blacks compared to 
whites, for age category 40-64 compared to older patients who are covered by Medicare, 
and among classes of lower socio-economic status. Joinpoint regression showed that 
the rate of decline in late-stage diagnosis for the two racial groups was similar among 
older patients (i.e. parallel time series). Both races displayed distinct spatial patterns 
with higher rates of late-stage diagnosis in the Florida Panhandle for white males 
whereas high rates clustered in South-eastern Florida for black males. ConClusions: 
The observed impact of socioeconomic and demographic factors on temporal trends 
in health outcomes emphasizes the need for local strategies and cancer control inter-
ventions to reduce late-stage diagnosis and improve health outcomes. Furthermore, 
large variations in the temporal trends in prostate cancer incidence and mortality and 
geographical variations would have important implications for resource allocation.
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objeCtives: Increased comorbid/mortality risk accompanies both excess weight 
and cancer. Charlson comorbidity index (CCI) scores in obesity and cancer 
were examined across two distinct populations and study designs. Methods: 
Comprehensive, electronic medical record (EMR) 2013 data from Clalit, a payer-
provider, closed-system health fund covering 55% of the Israeli population, were 
used to assess cancer diagnosis (vs. no cancer) and obesity (BMI≥ 30 vs. less) among 
individuals aged 21+ in Israel (n= 2,552,720). Similarly examined were 2013 adult 
(21+) respondents in the U.S. NHWS (n= 71,118), a cross-sectional, self-reported 
online survey. CCI, a weighted sum of comorbidities predicting mortality risk, was 
calculated based on registry diagnostic codes (Clalit) or self-reported diagnosis 
(NHWS). CCI categories and mean scores were compared across obesity/cancer 
groups and within age strata. Results: Proportions or patterns of individuals with 
CCI= 1+ were comparable across age brackets (21-49, 50-64, 65+) in Clalit (10.5%, 
43.3%, 66.7%, respectively) and NHWS (14.1%, 33.1%, 44.3%). CCI was higher among 
those with vs. without cancer (or obese vs. non-obese), all p< 0.05, among both 
Israeli (Clalit) and U.S. (NHWS) individuals. Across non-obesity/non-cancer, obesity/
non-cancer, non-obesity/cancer, and obesity/cancer groups, significantly increasing 
proportions of individuals had CCI= 1+ in both Clalit (23.4%, 41.9%, 68.7%, 77.2%, 
respectively) and NHWS (16.7%, 31.3%, 56.5%, 70.0%), plus increasing CCI means in 
Clalit (0.40, 0.80, 1.80, 2.10) and NHWS (0.25, 0.45, 1.38, 1.73), all p< 0.05. These pat-
terns replicated within the different age brackets. ConClusions: Across distinct 
data sources (Israeli insurance-clinical EMR and U.S. online survey), comparable 
comorbidity rates emerged within corresponding age brackets (notwithstanding 
“healthy cohort” effects observed among NHWS respondents aged 65+), and similar 
patterns of increased risk emerged with both cancer and obesity. This underscores 
the global challenge posed by the “dual-risk” profile of obesity with cancer history. 
Moreover, comprehensive and integrated EMR data can produce convergent results 
with validated, self-reported data, across diverse geographies.
age with mechanical stapling – which has potential to improve patient outcomes, 
lower re-operation rates and lower costs.
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objeCtives: Lung cancer is the first cause of cancer death in both men and women 
worldwide and 85% are NSCLC. As a targeted therapy for NSCLC, EGFR-TKIs has been 
compared with traditional chemotherapy in various trials in different countries 
but there is a lack of comprehensive literature review of these RCTs especially 
from Health-Related Quality of Life (HRQoL) perspective. We compared the effi-
cacy, safety and HRQoL between EGFR-TKIs(gefitinib, erlotinib and afatinib) and 
chemotherapy for advanced NSCLC patients with largest magnitude. Methods: 
Two authors independently searched published RCTs comparing EGFR-TKIs vs 
chemotherapy for advanced NSCLC between Jan 1, 1966 and July 31, 2013 in PubMed, 
Cochrane Library, EMBASE, the conference proceedings of ASCO and ESMO. We con-
ducted meta-analysis by Revman 5.0 using either random or fixed effects inverse 
variance weighted method, determined by heterogeneity levels. Results: Twenty-
two eligible studies and 6728 patients were included. Comparing to chemotherapy, 
EGFR-TKIs were superior in objective response rate (OR= 1.90, 95% CI= 1.32-2.57, 
P< 0.00001) and progression free survival (HR= 0.78, 95%CI= 0.66-0.91, P< 0.00001). 
However, no significant differences were observed on disease control rate (OR: 1.24; 
95% CI= 0.89-1.73), median overall survival (HR= 1.00; 95%CI= 0.93-1.07) and 1-yr 
survival rate (OR= 0.96; 95% CI = 0.82-1.13). EGFR-TKIs demonstrated less adverse 
events in neutropenia (OR= 0.01, 95% CI= 0.01-0.02), anemia (OR= 0.2, 95% CI= 0.14-
0.31), fatigue (OR= 0.18, 95% CI= 0.12-0.29) and nausea (OR= 0.35, 95% CI= 0.21-0.60) 
and less grade 3 or 4 adverse events (OR= 0.29, 95%CI= 0.26-0.33). However, chemo-
therapy had less rash (OR= 7.18, 95% CI= 4.67-11.05) and diarrhea (OR= 2.10, 95% 
CI= 1.49-2.98). In 8 studies evaluating the HRQoL, EGFR-TKIs had shown better out-
comes than chemotherapy according to the three HRQoL instruments: Functional 
Assessment of Cancer Therapy-Lung (OR= 1.62, 95% CI= 1.38-1.91), Trial Outcome 
Index (OR= 1.93, 95%CI= 1.61- 2.33), and Lung Cancer Subscale (OR= 1.19, 95%CI= 1.01-
1.39). ConClusions: Though no obvious survival benefit was observed, EGFR-TKIs 
demonstrated significantly better safety and HRQoL outcomes than chemotherapy.
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objeCtives: To determine the comorbidity burden and the association of specific 
pre-existing chronic-conditions with colorectal cancer (CRC) stage-at-diagnosis, 
treatment, and survival among elderly Medicare beneficiaries from a rural popula-
tion. Methods: This population-based retrospective cohort study used data on 
fee-for-service Medicare beneficiaries diagnosed with CRC and chronic-conditions 
between 2003-2006, identified from the West Virginia Cancer Registry (WVCR)-
Medicare linked database (n= 2,119). Beneficiaries were classified in specific chronic-
condition clusters. CRC-treatment received was ascertained from beneficiaries’ 
Medicare claims by following them for 12-months from their CRC-diagnosis date 
or until death. Receipt of minimally-appropriate CRC treatment (MACT) as defined 
by National Cancer Institute CRC-treatment guidelines and receipt of CRC-related 
surgery, chemotherapy, and radiation were examined. All-cause and CRC-specific 
mortality in the 36-month period following the CRC-diagnosis were examined, 
after accounting for selection bias using inverse probability treatment weights and 
adjusting for socio-demographics, cancer site and stage-at-diagnosis, receipt of 
MACT, and pre-existing conditions. Results: The WVCR-Medicare linked data-
base had a higher proportion of beneficiaries as compared to those from national 
data across almost all the condition clusters including previous-malignancy, COPD, 
depression, gastrointestinal conditions, heart-conditions, hypertension, liver-
conditions, and renal-conditions. Beneficiaries from the WVCR-Medicare linked 
database with most chronic-conditions were generally not likely to be diagnosed at 
distant-stage CRC, and possibly not as less aggressively treated for CRC as reported 
by some other studies. Only a few conditions were negatively associated with CRC-
specific mortality including depression (adjusted hazards ratio (AHR)= 1.25;95%CI
= [1.08,1.46]), and liver-conditions (AHR= 1.38;95%CI= [1.19,1.60]). However, almost 
all chronic-conditions were negatively associated with all-cause mortality in this 
study. ConClusions: This study highlights the need to focus on cancer-care that 
is better integrated with co-management of chronic-conditions, especially among 
those from rural-areas who are likely to have a high comorbidity burden.
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objeCtives: To account for the non-stationarity of relationships in space, aspatial 
regression can be supplemented with geographically-weighted regression (GWR), 
whereby the regression model is fitted within local windows and each observation 
is weighted according to its proximity to the center of the window. This study aims 
to conduct regression analysis in a spatial context to assess the local impacts of 
putative factors on late-stage diagnosis of prostate cancer in Florida during the 
